Vision Disorders Clinical Trial
— MacuFixOfficial title:
Usability of the Software MacuFix for the Categorization of Metamorphopsia and Evaluation of Patient Adherence Compared to the Amsler Grid
NCT number | NCT04347564 |
Other study ID # | metacat |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 4, 2020 |
Est. completion date | September 30, 2020 |
Verified date | May 2021 |
Source | Augenheilkunde Lindenthal |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The usability of a novel test to categorize a distorted visual impression (metamorphopsia) is examined with the questionnaire "SUS"
Status | Completed |
Enrollment | 45 |
Est. completion date | September 30, 2020 |
Est. primary completion date | September 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Distorted visual impression in at least one eye, detected with Amsler grid: 2. Best-corrected visual acuity (BCVA): at least 20/200; age over 18 years; presence of a declaration of consent to participate in the study Exclusion Criteria: No distorted visual impression in both eyes; best corrected visual acuity under 0.1; age under 18 years |
Country | Name | City | State |
---|---|---|---|
Germany | Augenheilkunde Lindenthal | Cologne |
Lead Sponsor | Collaborator |
---|---|
Augenheilkunde Lindenthal |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Score of System Usability Scale (SUS) Questionnaire | Patients filled out the SUS questionnaire immediately after completing the MacuFix test. SUS consists of ten statements each with five possible answers ranging from complete rejection to complete agreement. For each statement, the participant gives his or her approval or rejection in the form of a scale ranging from 1=strong approval to 5=strong rejection. The results of the SUS questionnaire are used to calculate a numerical value (SUS score).The results can have a value between 0 (worst application imaginable) and 100 (best application imaginable) | 1 day | |
Secondary | Median Time Interval (in Days) Between Two Self-test Measurements (MakuFix or Amsler Respectively) to Assess the Test Adherence | After a positive vote by the Ethics Committee of the North Rhine Medical Association (No. 2020057) 45 patients were included in the study from 4th May, 2020 - 30th June, 2020. Based on the amendment approval of the competent ethics committee (No. 600213225) participating persons were offered to use the App MacuFix® as a home test and to start a prospective, controlled study to examine the adherence using a self-test and evaluate the vison-related quality of life.
On the study day and 3 months later each patient was asked about the frequency of use of the Amsler test. The time interval given by the patient between two Amsler Tests (Amsler group) or two MacuFix texts (MacuFix group) was assessed in days. |
On the study day and 3 months after the study day, patients were asked how many days usually elapsed after a test with the method they chose until the next time they used this test method. | |
Secondary | Change of Vision-related Quality of Life (NEI VFQ-25, Subscale 7) After Use of the App MacuFix Versus Amsler Grid/no Test | The validated questionnaire "National Eye Institute Visual Function Questionnaire-25" (NEI VFQ-25) was used to measure vision-related quality of life. The values in the questionnaire can take values from 0 to 100. High values in this questionnaire correspond to a better quality of life, low values to a poor quality of life. The 25 questions of this questionnaire can be assigned to 12 scales. | The validated questionnaire "National Eye Institute Visual Function Questionnaire-25" (NEI VFQ-25) was used at baseline and after 3 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03872479 -
Single Ascending Dose Study in Participants With LCA10
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02595502 -
Clinical Evaluation of Two Silicone Hydrogel Daily Disposable Contact Lenses
|
N/A | |
Completed |
NCT02485054 -
A Predictive Score for the Ischemic Etiology of a Transient Visual Disturbances (VASCO)
|
||
Completed |
NCT00985231 -
Performance Evaluation of Contact Lenses Among a Population of Adapted Contact Lens Wearers
|
N/A | |
Recruiting |
NCT05208658 -
Characteristics of the Vergence Responses of Binocularly Normal Subjects After a Vision Therapy Protocol
|
N/A | |
Recruiting |
NCT06077682 -
Cycloplegic Refraction in Pediatric Patients With Esotropia
|
Phase 4 | |
Active, not recruiting |
NCT04123626 -
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
|
Phase 1/Phase 2 | |
Recruiting |
NCT04693247 -
Handheld Device Compared With a Standard Eye Care Diagnostic Device in Measuring Ophthalmic Refraction
|
N/A | |
Recruiting |
NCT06451172 -
Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
|
Early Phase 1 | |
Completed |
NCT01318577 -
Study of A New Contact Lens Cleaning and Disinfecting Solution
|
N/A | |
Completed |
NCT03763721 -
The ADVISE Study: Advanced Visualization In Corneal Surgery Evaluation
|
N/A | |
Completed |
NCT05602402 -
To Evaluate the Efficacy and Safety of CAEP-01 on Eye Strain in Children With Heavy Screen Use
|
N/A | |
Not yet recruiting |
NCT06085430 -
Kubota Glass Parameter Refinement Study
|
N/A | |
Completed |
NCT01698788 -
Effect of Intraoperative Dexamethasone Implant in Taut Posterior Hyaloid Removal in Diabetic Macular Edema
|
N/A | |
Completed |
NCT01546402 -
Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema
|
Phase 4 | |
Completed |
NCT03169855 -
Validation of Mesopic and Photopic Contrast Vision Tests With Respect to Nighttime Driving Ability
|
||
Terminated |
NCT03913130 -
Extension Study to Study PQ-110-001 (NCT03140969)
|
Phase 1/Phase 2 | |
Recruiting |
NCT03479021 -
SPOT Vision Screening
|
||
Recruiting |
NCT05600140 -
Viewing Strategy Training in Children With (Cerebral) Visual Impairment
|
N/A | |
Completed |
NCT03780257 -
Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene
|
Phase 1/Phase 2 |